Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310915 | 0.92 | LOXL2 (0.53) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL9231249 | 0.88 | MMP8 (0.50) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL2692900 | 0.87 | LDHA (0.62) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL20168295 | 0.86 | LOXL2 (0.58) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL24934349 | 0.84 | LOXL2 (0.56) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL9317096 | 0.82 | LDHA (0.52) | KMT2ALDHATSHR | |
| SCHEMBL2331067 | 0.82 | LOXL2 (0.58) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL15772079 | 0.81 | LOXL2 (0.61) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL765010 | 0.81 | LOXL2 (0.61) | LOXL2CYP4A11CYP4F2CA1CA2 | |
| SCHEMBL28332902 | 0.81 | MMP8 (0.54) | LOXL2CYP4A11CYP4F2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935847-B2 | Nitroxyl ion source with second order reaction nitroxyl release | DUKE UNIVERSITY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935847-B2 | Nitroxyl ion source with second order reaction nitroxyl release | DUKE UNIVERSITY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935847-B2 | Nitroxyl ion source with second order reaction nitroxyl release | DUKE UNIVERSITY (US) | 2011-05-03 | — | — | US | disclosed |
| US-20100094060-A1 | NITROXYL ION SOURCE WITH SECOND ORDER REACTION NITROXYL RELEASE | DUKE UNIVERSITY (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100094060-A1 | NITROXYL ION SOURCE WITH SECOND ORDER REACTION NITROXYL RELEASE | DUKE UNIVERSITY (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100094060-A1 | NITROXYL ION SOURCE WITH SECOND ORDER REACTION NITROXYL RELEASE | DUKE UNIVERSITY (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2008130566-A1 | NITROXYL ION SOURCE WITH SECOND ORDER REACTION NITROXYL RELEASE | DUKE UNIVERSITY (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130566-A1 | NITROXYL ION SOURCE WITH SECOND ORDER REACTION NITROXYL RELEASE | DUKE UNIVERSITY (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2004096808-A1 | TRIAZINE COMPOUNDS AND THEIR USE | DE NOVO PHARMACEUTICALS LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| US-5453514-A | Diabetes | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1995-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094060-A1 | NITROXYL ION SOURCE WITH SECOND ORDER REACTION NITROXYL RELEASE | NOS2, NOS1, NOS3 | LOXL2 1409/4885CYP4A11 271/4885CYP4F2 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.